|
SLC25A32 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.95459998081549E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.65220004344491E-09 |
| Normal-vs-Stage2 |
1.9304999820946E-09 |
| Normal-vs-Stage3 |
1.32699962129834E-10 |
| Normal-vs-Stage4 |
1.30599997483216E-09 |
| Stage1-vs-Stage2 |
2.874800E-01 |
| Stage1-vs-Stage3 |
4.963400E-01 |
| Stage1-vs-Stage4 |
1.217600E-01 |
| Stage2-vs-Stage3 |
6.653600E-01 |
| Stage2-vs-Stage4 |
7.143200E-01 |
| Stage3-vs-Stage4 |
4.171600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.21349996717868E-09 |
| Normal-vs-AfricanAmerican |
1.08529999998108E-06 |
| Normal-vs-Asian |
1.32880000336399E-08 |
| Caucasian-vs-AfricanAmerican |
9.893600E-01 |
| Caucasian-vs-Asian |
7.162400E-01 |
| AfricanAmerican-vs-Asian |
8.022400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.32782673745169E-13 |
| Normal-vs-Female |
1.3500000006772E-09 |
| Male-vs-Female |
7.710100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.14629999936611E-08 |
| Normal-vs-Age(41-60Yrs) |
3.16420223356317E-11 |
| Normal-vs-Age(61-80Yrs) |
6.3432037400446E-11 |
| Normal-vs-Age(81-100Yrs) |
2.101000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.719930E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.295600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.128000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.568200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.603450E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.120800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.581400E-01 |
| Classical-VS-Follicular |
2.142500E-03 |
| Classical-VS-Other |
1.160830E-01 |
| Classical-VS-Normal |
3.44749999658944E-08 |
| Tall-VS-Follicular |
4.311000E-01 |
| Tall-VS-Other |
3.332200E-01 |
| Tall-VS-Normal |
1.36080000046057E-07 |
| Follicular-VS-Other |
5.870200E-01 |
| Follicular-VS-Normal |
5.87040416277773E-11 |
| Other-VS-Normal |
7.248500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.52250434481971E-11 |
| Normal-vs-N1 |
2.16550000153859E-08 |
| N0-vs-N1 |
3.974000E-01 |
|
|
